Archelis is a Yokohama-based hardware startup with a mission to free humanity from the pain and injury of standing work. The company was born out of its founder and CEO Hideyuki Fujisawa’s project to use his engineering expertise to develop gear for doctors to reduce their physical burden from standing while performing surgery in response to a physician’s request. The company’s first product, “archelis” has received numerous awards, including a reddot award (2020) and a Silver Award in IAUD’s (International Association for Universal Design) International Design Award (2019).
RUN. EDGE Limited is a startup company, which was carved out of Fujitsu Limited. With the mission of "Creating new experiences through video and technology”, RUN. EDGE provides video search and real-time analysis platforms in the sports and enterprise fields including education.
Citadel AI helps AI teams to monitor and test their AI applications. Over 80% of AI applications fail in real world deployments due to data quality issues, and our products automatically detect and mitigate these problems. We aim to be "the Datadog for AI".
Wayfarer is leading digital transformation in hospitality with our tech-enabled management brand. We've raised $2 million in funding from property investors who deeply understand the problems and inefficiencies in the hospitality business model, allowing us to grow our unit count by 5x in the last year to drive $3 million annualized revenues. Founded in November 2019 with just an idea, we now have 200 rooms operated and contracted for total assets under management of nearly $50 million in partnership with global property investors and listed Japanese real estate companies. Our vision is to develop a white-label hospitality SaaS platform that redefines the $200 billion hospitality market in Asia.
ListenField is an AgTech startup created by academic researchers that specializes in the gathering, processing, and analysis of multilayer data. We provide insightful information to agro professionals, allowing them to make better decisions to optimize their production capabilities.
Vox provides a personalized vending box where people can get essentials and groceries in 10sec., having access 24/7, in their on-premise. Vox serves people seeking a way to get better items quickly at an affordable price with minimum stress on the brain with saving more time.
We transform the industry with technology and make "human energy" the highest value. We develop services mainly for the entertainment industry. We are developing a minute-by-minute scheduling application for use at events and a revenue-sharing streaming service that applies blockchain technology.
Qurate is a SaaS (Software as a Service) company pioneering the development of Marketing Technology (MarTech) helping companies to deliver revenue growth through digital marketing transformation. Specializing in social media, content marketing and website management platforms, Qurate has a global presence providing world-class development and education to companies all over the world with offices in Japan and the UK. Qurate was founded in Fukuoka in 2014 by Tom Brooke.
We create secure computing systems that process over always encrypted data, ensuring that no information is exposed at any stage - keeping data safe throughout its lifecycle. We build on this to develop AI systems that enable access to knowledge contained within data without revealing the contents - giving back control over information to its respective owners.
Robots require a map just like humans do.With such a map robots can operate well autonomously. We believe we can make a programmable world. We are not a map company for humans but for robots. Robots include drones, wheel chairs, autonomous vehicles (AV), construction robots and bikes.
From its establishment in 2005, J-Pharma, a clinical stage bio-venture company with a special focus on membrane transporters, has been conducting an array of unique drug developments by Hitoshi Endou, MD., Ph.D., formerly a professor of Kyorin University Faculty of Medicine. Recently J-Pharma has been placing the highest priority on the clinical development of its original inhibitors of L-type amino acid transporter 1 (“LAT1”) for the treatment of advanced cancer patients who failed to benefit from standard chemotherapy.
Sonire has developed Next Gen US-guided HIFU therapy system using technology and know-how generated by Tokyo Women’s Medical University, Tohoku University and Tokyo Medical University for cancer treatment. It is expected to be a new therapeutic modality for intractable cancer like pancreatic cancer.
We produce and provide homogeneous and high precision human blood cells to drastically streamline the evaluation of efficacy and safety of drug candidates and functional materials, as well as the research of infectious diseases. We also sell evaluation kits and offer various contract evaluation services.
CarbGeM aims to overcome the problem of antimicrobial resistance through cutting-edge biology and digital technology, cross-industrial and cross-disciplinary collaboration including medicine and engineering, and industry-government-academia collaboration with world leading hospitals and research institutions. Our AI-based product assists physicians and laboratory technicians in estimating the species of bacterial infections and selecting appropriate antimicrobial agents.
iCorNet.Laboratory Co. is an academia driven medical device venture from Nagoya University Japan, developing the cardiac support net for heart failure and Lethal arrhythmia. Our device for HF is Patient-Specific Design and Manufactured by 3D knitting machine individually. It fills the treatment gap between ongoing drug therapy and heart transplantation (HTx), and is an alternative to Ventricular Assist Device (VAD)．Our device for lethal arrhythmia (ICD cardiac net) proves painless defibrillation (<0.7J) in both large animal model and computer simulation. Both devices have possibility to be gamechangers of current treatments.
aceRNA Technologies is a biotech startup established in 2018 based on RNA design technology developed in synthetic RNA biology research by Prof. Hirohide Saito at Kyoto University. We are developing "smart gene therapy” (mRNA-based and virus-base) that enables control of therapeutic transgene expression in cell-type and -state specific manner.
Celaid Therapeutics is an early stage Japan-based startup company that is based on the novel ex vivo expansion technology of hematopoietic stem cell invented at University of Tokyo and University of Tsukuba. Our mission is to develop cell therapy products that will be the next-generation stem cell transplantation.
A startup company from Keio University School of Medicine and Nagoya Institute of Technology, developing a visual restoration gene therapy using AAV (adeno-associated virus) vectors with the unique function gene “Chimeric Rhodopsin” to treat blindness.
atDose was founded on September 1, 2017 in Yokohama City, Kanagawa, Japan. We are developing a mobile-type dosing and infusion device that can dispense ultra-small doses at precise target points. The lightweight portable intravenous device can be used to support the treatment of diseases such as brain tumors, retinal disease, and breast cancer. With this device, we aim to create a medication platform that will fundamentally change the conventional treatment of serious diseases. For example, side effects such as stomatitis, hair loss, and nausea with anticancer drugs are one of eternal difficulty of medicine. Our ultra-micro-dosing device enables localized, targeted and continuous dosing. Thus, side effects should be reduced while maintaining the efficacy of the drug. Since an animal study has proved our device efficacy, we can go through clinical trial of any cancer therapy. Furthermore, any drug combination can be freely applied with newly approvable dosing amount, therefore, our device will be a novel drug delivery system as a platform technology. We also aim to improve patients' Quality of Life (QoL) with increasing the option of medication procedure. In addition to the conventional treatment, our platform technology will provide an additional procedure that respects patients' preference of QoL . We strongly believe this will improve present medication.
AC Biode is a Japanese-European cleantech startup with expertise in chemistry, electronics and material science.
Kyoto Fusioneering is a privately held technology start-up founded in 2019, with its headquarters in Kyoto, Japan. The company is focused on developing advanced technologies for commercial fusion reactors, including gyrotron systems, tritium fuel cycle technologies, and breeding blankets for tritium production and power generation. The company is focused on innovative solutions that are simultaneously high-performance and commercially viable. Supporting both public and private fusion developers around the world, the company will accelerate the realization of fusion as the ultimate energy source for humankind.
The company is developing a unique microwave-excited surface wave plasma process to deposite graphene directly on aribrary susbtrates. Thus, the company gives various solutions for graphene formation on susbtrates like, plastics, glass, metals, dielectric and insulators. The graphene deposited technology has been extented to fabricate graphene-silicon solar cells, graphene coated peroveskite solar cells, all-solid-state lithium ion batteries and fuel cells.
We are currently working on the following projects. Extraction of magnesium and lithium from the sea, smelting magnesium hydroxide into pure magnesium to be used as a raw material for magnesium alloys, supply of domestically produced low-CO2 magnesium as a constituent material for next-generation key industries such as automobiles and robots by overcoming the situation where China accounts for more than 80% of the world's production. To recover CO2 from various sources, such as thermal power generation and atmospheric CO2, generate heat and electricity through a power generation system using the combustion reaction between magnesium and CO2. Furthermore, we aim to kill two birds with one stone by recovering CO2 from many sources, such as thermal power generation and CO2 in the atmosphere, and generating heat and electricity through a power generation system using the combustion reaction of magnesium and CO2 to reduce CO2.
We have been working to bring unique acoustic inventions to markets for 16 years. Located in Tokyo, Japan. First product was a medical device called "Lung Flute" and it is currently used to find active Tuberculosis cases in developing countries. Now, we have developed and patented a new tire technology to contribute for future mobility society.
We solve the challenging environmental problem of clogged and damaged pipes without using chemicals with our Ultra Fine Bubble (UFB) technology which produces nano-sized bubbles for a unique and natural cleaning effect. Over 7,000 customers in Japan trust our technology, UFB DUAL. Satisfied Japanese customers come from industries including medical, housing, factories, hotels, and more! By using UFB, our customers save money, reduce labor and save the environment. We partner with developers, LEED focused building owners.
Chinese chat marketing service 「ChiChat」 The EC brand have two problems, we resolve these problems 1.Getting new user CPA is high 2.Existing user’s LTV is not grown up 1.Explaining products by the chat, can reduce CPA 2.Having continuous chats by the push messages, can make LTV grow up
XELA Robotics produces "uSkin", tactile sensors that enable robots to perform tasks with their hands that previously only humans could do, like gently grasping objects. Our products can be used for example in assembly robots or for warehouse automation.
Tenchijin, certified by JAXA, delivers its « Land Evaluation Engine ». It evaluates the characteristics and potential of the fields to support companies run their business at the best places and with right and sustainable practices, especially for agriculture, city development, disaster management.
We are a startup to develop a novel tiny particle for unmet medical needs such as cancer and chronic pain, which particle is self-targeting to the tumor vessel, repeatable and degradable as a platform technology for further applications. Our unique particle is patent granted in Japan, now under transferring to the US, EU and China now. The first indication for human clinical trial will be HCC (hepato-cellular carcinoma) to replace TACE (trans-catheter chemoembolization) treatment which is the current primary option for the intermediate stage of HCC and to be a primary option other than shifting to chemotherapy. The other advantages are universal to every solid tumor, locoregional work at tumor tissue only, combinatory because of drug free and gentle for the weaken patient without additional physical burden. We can expect the extension of PFS (progression free survival) and OS (overall survival) rather than the high response of the advanced chemotherapy such as molecular target medicine and immunotherapy with severe side effects and drug escalations. The potential market for liver cancer only will be near 1 billion dollars per year. So, after the extension to the other solid tumors, it will be easily over several billions. The current definition of our particle is a medical device (category III by FDA), but it can become a functional matter after labeling other functions as a medicine. We are looking for the investors, collaboration partners and medical institutions for the global clinical trials.
Pale Blue is a Japanese aerospace company that develops and manufactures next-generation spacecraft engines. Developed in close collaboration with the Japanese Space Agency (JAXA), Pale Blue's proprietary engines use water as fuel and is able to achieve unprecedented levels of thrust and fuel efficiency. As water is one of the world's safest, most environmentally sustainable, and affordable propellants available today, Pale Blue seeks to disrupt the space mobility industry and accelerate humankind's drive to commercializing and expanding the space economy.
In Japan we suffer from a super-aging society. This aging population issue poses an urgent challenge to the medical sector. We need faster discharge rates at hospitals in order to stable revenue models and profitability. We can solve this problem with our proprietary technology - SAA.
Hynts Tech is a university startup established in July 2021. We develop and manufacture tools for introducing substances such as DNA, RNA, proteins, or intracellular organelles into cells, or for extracting intracellular materials, and to process cells using these tools.